Osteoboost: Thiết bị đeo hỗ trợ sức khỏe xương đã được FDA phê duyệt, hiện đã có sẵn đặt hàng trước

Osteoboost: Thiết bị đeo hỗ trợ sức khỏe xương đã được FDA phê duyệt, hiện đã có sẵn đặt hàng trước

Công ty Công nghệ Sức khỏe Xương (Bone Health Technologies – BHT) đã mở đặt hàng trước cho Osteoboost, thiết bị y tế đeo được đầu tiên được Cục Quản lý Thực phẩm và Dược phẩm Hoa Kỳ (FDA) phê duyệt, được thiết kế để điều trị chứng loãng xương, một tình trạng ảnh hưởng đến hàng triệu người có nguy cơ bị gãy xương. Thiết bị này là một phương pháp điều trị không xâm lấn, không dùng thuốc dành cho phụ nữ mãn kinh có mật độ xương thấp. Với giá 995 đô la trong giai đoạn đặt hàng trước (so với giá niêm yết 1.500 đô la), Osteoboost dự kiến sẽ được giao hàng trong vòng 60–90 ngày.

#Osteoboost #LoangXuong #SucKhoeXuong #FDA #ThietBiDeo #CongNgheYTe #PhuNuManKinh #MatDoXuong #DieuTriKhongThuoc #BoneHealth #WearableTech #HealthTech #Innovation #MedicalDevice

                Bone Health Technologies (BHT) has opened pre-orders for <strong>Osteoboost</strong>, the first FDA-cleared wearable medical device designed to treat osteopenia, a condition affecting millions at risk of fractures.

The device is a non-invasive, non-drug treatment option for postmenopausal women with low bone density. Priced at $995 during the pre-order phase (compared to a $1,500 list price), Osteoboost is expected to ship in 60–90 days.

Osteoboost uses precision vibration therapy to target the hips and spine—areas most susceptible to osteoporotic fractures. The device’s patented technology dynamically calibrates vibration frequency and amplitude to slow bone density loss and enhance bone strength.

Clinical trials demonstrated significant efficacy, reducing spine bone density loss by 85% and bone strength reduction by 83%. Participants in the trials praised the device for its ease of use and comfort, integrating it seamlessly into daily activities.

The innovation stems from rigorous research led by Dr. Michael Jaasma, Chief Scientific Officer at BHT, who focused on the effects of mechanical stimulation on bone cells. The device mimics the benefits of high-impact exercise, leveraging vibration therapy to stimulate bone regeneration. Experts like Dr. Yevgeniya Kushchayeva, an endocrinologist specializing in bone density therapies, highlight Osteoboost’s potential, citing its foundation in proven bone science.

The release of Osteoboost marks a significant milestone for BHT, which has spent years navigating the FDA De Novo clearance process and conducting pivotal clinical trials. The company plans to accelerate production to meet high demand, as a Founder’s Program for early adopters has already sold out.

The device will begin shipping on a first-available basis in the next 2-3 months. Pre-ordering is available here.

MEDICAL DISCLAIMER:
THIS WEBSITE DOES NOT PROVIDE MEDICAL ADVICE.
The information provided on this website is intended for educational and entertainment purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Ubergizmo and its writers are not medical professionals and do not offer medical or health advice of any kind. We do not endorse or recommend any specific tests, healthcare providers, treatments, products, procedures, opinions, or other information mentioned on this website. Any reliance you place on the information found on Ubergizmo, including content created by its employees, contributors, or others invited to participate, is strictly at your own risk. Always consult a licensed physician or qualified healthcare provider for medical advice regarding a specific condition or treatment. Never disregard or delay seeking professional medical advice because of something you have read on this website.In case of a medical emergency, contact your doctor or call emergency services immediately.

                 <!-- Web Push subscription button-->
                <p>Filed in <span id="breadcrumbs">Medical</span>. Read more about  Fda, Medical and Medicine. </p>